Media headlines about CEL-SCI (NYSEMKT:CVM) have trended somewhat negative recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. CEL-SCI earned a news sentiment score of -0.02 on Accern’s scale. Accern also gave news headlines about the company an impact score of 80 out of 100, indicating that recent news coverage is likely to have an effect on the stock’s share price in the immediate future.
Shares of CEL-SCI (CVM) traded up 1.80% during trading on Tuesday, hitting $1.70. The stock had a trading volume of 145,955 shares. The stock’s 50-day moving average price is $0.24 and its 200 day moving average price is $0.14. CEL-SCI has a one year low of $0.06 and a one year high of $2.05. The stock’s market cap is $15.63 million.
CEL-SCI (NYSEMKT:CVM) last released its quarterly earnings data on Wednesday, May 10th. The company reported ($0.05) earnings per share (EPS) for the quarter. The company had revenue of $0.02 million for the quarter. CEL-SCI had a negative return on equity of 4,970.98% and a negative net margin of 48,949.30%. On average, equities analysts forecast that CEL-SCI will post ($0.42) EPS for the current year.
CEL-SCI Company Profile
CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines.
Receive News & Ratings for CEL-SCI Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI Co. and related companies with MarketBeat.com's FREE daily email newsletter.